<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Directorship &#124; Boardroom Intelligence &#187; Pfizer</title>
	<atom:link href="http://www.directorship.com/tag/pfizer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.directorship.com</link>
	<description>Boardroom Intelligence</description>
	<lastBuildDate>Fri, 03 Feb 2012 18:48:26 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Seven for Yo-leven</title>
		<link>http://www.directorship.com/seven-for-yo-leven/</link>
		<comments>http://www.directorship.com/seven-for-yo-leven/#comments</comments>
		<pubDate>Thu, 24 Mar 2011 01:04:33 +0000</pubDate>
		<dc:creator>Patrick McGurn</dc:creator>
				<category><![CDATA[Articles & Research]]></category>
		<category><![CDATA[Home Highlight News Story]]></category>
		<category><![CDATA[Magazine]]></category>
		<category><![CDATA[Shareholder & Proxy]]></category>
		<category><![CDATA[afl-cio]]></category>
		<category><![CDATA[Air Products and Chemicals]]></category>
		<category><![CDATA[Airgas]]></category>
		<category><![CDATA[Amalgamated Bank’s LongView funds]]></category>
		<category><![CDATA[Barney Frank]]></category>
		<category><![CDATA[BJ's Wholesale Club]]></category>
		<category><![CDATA[bp]]></category>
		<category><![CDATA[business roundtable]]></category>
		<category><![CDATA[CalPERS]]></category>
		<category><![CDATA[Calstrs]]></category>
		<category><![CDATA[Calvert Asset Management]]></category>
		<category><![CDATA[Charles River Laboratories]]></category>
		<category><![CDATA[chris dodd]]></category>
		<category><![CDATA[Community Health Systems]]></category>
		<category><![CDATA[Council of Institutional Investors]]></category>
		<category><![CDATA[Dodd-Frank Act]]></category>
		<category><![CDATA[Don Blankenship]]></category>
		<category><![CDATA[Florida State Board of Administration]]></category>
		<category><![CDATA[Genzyme]]></category>
		<category><![CDATA[Henry Meyers]]></category>
		<category><![CDATA[house financial services committee]]></category>
		<category><![CDATA[ISS]]></category>
		<category><![CDATA[ISS Governance Services]]></category>
		<category><![CDATA[Jeffrey Kindler]]></category>
		<category><![CDATA[John Chevedden]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Korn/Ferry]]></category>
		<category><![CDATA[Laborers’ International Union of North America]]></category>
		<category><![CDATA[Leonard Green]]></category>
		<category><![CDATA[LIUNA]]></category>
		<category><![CDATA[Mark Hurd]]></category>
		<category><![CDATA[Massey Energy]]></category>
		<category><![CDATA[MDU Resources]]></category>
		<category><![CDATA[MSCI]]></category>
		<category><![CDATA[navistar international]]></category>
		<category><![CDATA[NYCERS]]></category>
		<category><![CDATA[Occidental Petroleum]]></category>
		<category><![CDATA[Patrick McGurn]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray Irani]]></category>
		<category><![CDATA[Relational Investors]]></category>
		<category><![CDATA[Rob Feckner]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[say on frequency]]></category>
		<category><![CDATA[say on pay]]></category>
		<category><![CDATA[sec]]></category>
		<category><![CDATA[Spencer Bachus]]></category>
		<category><![CDATA[Teamsters General Fund]]></category>
		<category><![CDATA[Ted Allen]]></category>
		<category><![CDATA[Tenet Healthcare]]></category>
		<category><![CDATA[the Connecticut Retirement Plans & Trust Funds]]></category>
		<category><![CDATA[Towers Watson]]></category>
		<category><![CDATA[U.S. Chamber of Commerce]]></category>
		<category><![CDATA[United Brotherhood of Carpenters]]></category>
		<category><![CDATA[Walden Asset Management]]></category>
		<category><![CDATA[Whilshire Consulting]]></category>

		<guid isPermaLink="false">http://www.directorship.com/?p=22026</guid>
		<description><![CDATA[<p>Directors roll the dice in 2011 proxy season craps game.</p>
]]></description>
			<content:encoded><![CDATA[<p>My annual search for a theme to encompass the impending proxy campaign led to a dicey encounter with a colleague who dabbles in both governance and gambling. Knowing my tendency to tie themes to the year’s final two digits, the frequent visitor to both Las Vegas casinos and governance confabs put his money down on the craps table. “Yo-leven is a natural,” he said.</p>
<p><a href="http://www.directorship.com/media/2011/02/ARTICLE-Proxy2.jpg"><img class="alignleft size-full wp-image-22050" style="border: 0pt none;" title="ARTICLE-Proxy" src="http://www.directorship.com/media/2011/02/ARTICLE-Proxy2.jpg" alt="" width="400" height="296" /></a>While I had planned on a football theme with eleven players on either (take your pick) the U.S. gridiron or the rest-of-the-world’s pitch, the governance guru/gambler’s remark required research. After a Google and a few Wikis, I learned that initial rolls of the dice that add up to either seven or eleven are “natural” winners at the craps table. Eleven is called out at the table as “yo-leven” (or “yo”) due to the potential for confusion given the similar sound of seven.</p>
<p>As I pictured the bevy of boardroom requirements tumbling out of the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank), it hit me that a roll of the dice would more than suffice as the 2011 season’s symbol. While directors will not imagine that they are in the Nevada desert once the say-on-pay tsunami makes landfall, they may feel like riverboat gamblers—slightly queasy and desperately seeking terra firma. The deal-sealer was an obscure Wiki factoid: craps devolved from an old English dice game called “hazard.”</p>
<p>So without further ado, here is a list of seven potentially hazardous points that directors should prepare to roll when they step up to the boardroom craps table for the yo-leven proxy season.</p>
<p><strong>Democrats’ Snake Eyes Roll May Roil Directors</strong><br />
The 2010 annual meeting season was quiet thanks to all of the noisemaking in the nation’s capital. In the wake of the Wall Street-driven market meltdown, all eyes locked onto K Street and Capitol Hill. Many activists actually down shifted their 2010 annual meeting efforts in favor of a march on Washington D.C.</p>
<p>This capital investment paid dividends as Dodd-Frank looked like it would tip the governance table in activists’ direction for 2011 and beyond. Reformers were on a hot steak last summer as Congressional stick men Senator Chris Dodd and Representative Barney Frank passed loaded dice over to the Securities and Exchange Commission (SEC). With the long-coveted cover of Congressional authorization, the Commission adopted its proxy access rules in August 2010 and began implementing Dodd-Frank’s say-on-pay mandates.</p>
<p>Before the winning chips were pushed across the table, however, the U.S. Chamber of Commerce and the Business Roundtable asked the U.S. Court of Appeals for the D.C. Circuit to invalidate the SEC’s access rule. In October 2010, the Commission shocked the good-governance crowd by staying the effectiveness of the rules pending resolution of the legal challenge.</p>
<p>Next, in early November 2010, Washington’s reign as the epicenter of the governance universe abruptly ended when Congressional Democrats rolled snake eyes in the mid-term elections. The subsequent musical chairmen game led to an ideological sea change in the U.S. House of Representatives as Alabama Republican Spencer Bachus replaced Massachusetts Democrat Barney Frank as chair of the House Financial Services Committee. Rep. Bachus promised to go title-by-title through his predecessor’s namesake Act to “correct, replace or repeal the job killing provisions that unnecessarily punish small business and community banks that did nothing to cause the financial crisis.”</p>
<p>The odds of Dodd-Frank’s repeal are low since Democrats still control both the U.S. Senate and the White House. Undaunted, newly installed Republican committee chairs have already begun to harass agency rule writers—via tough oversight—and to starve—via slow, low or zero appropriations—the SEC and the various new bureaucracies envisioned by Dodd-Frank.</p>
<p>Without the promise of further governance changes via Federal fiat and with proxy access offline, directors should prepare for bumper crops of shareholder proposals, letter-writing campaigns, “just vote ‘no’” efforts and old-school proxy fights this year. Notably, activists have turned their attention to the leftovers—especially majority threshold voting (MTV) in uncontested elections—from last year’s Congressional chow down at the governance buffet.</p>
<p><strong>Boards Weigh Odds of Activists Rolling Hard Six</strong><br />
As a result of the SEC’s stay, the Commission’s rule (14a-11), which would have become effective on Nov. 15, 2010, sits in limbo. Even assuming the Federal courts uphold the rule, implementation will not come in time to impact the 2011 proxy campaign. The SEC stay also delays amendments to Rule 14a-8 that would have allowed investors to file bylaw proposals creating more permissive access procedures.</p>
<p>While 14a-11 nominees and 14a-8 bylaws will not appear on 2011 ballots, some activists have begun to build the infrastructure that will allow them to exploit access once it is up and running. The rule, if implemented, will require wannabe shareholder nominators to roll six the hard way—owning at least three percent of a public company’s voting stock for at least three years. That means only big players need apply. Some mega-money managers tell us that they have already received feelers from activists who seek to gauge their future interest in joining coalitions to clear the three-percent/three-year hurdle.</p>
<p>Two of the market’s highest rollers, the $220 billion California Public Employees Retirement System (CalPERS) and the $140 billion California State Teachers&#8217; Retirement System (CalSTRS), are rounding up possible candidates for boards. The two fund giants partnered in 2010 to develop a database of potential shareholder-friendly director candidates with diverse talents. This “Diverse Director Database,” or 3D, opened last year and the funds are fielding resumes.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.directorship.com/seven-for-yo-leven/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Postings: Pfizer’s Board Formalizes Advisory Vote</title>
		<link>http://www.directorship.com/pfizer-advisory-vote/</link>
		<comments>http://www.directorship.com/pfizer-advisory-vote/#comments</comments>
		<pubDate>Tue, 15 Dec 2009 20:06:47 +0000</pubDate>
		<dc:creator>Gretchen Michals Salois</dc:creator>
				<category><![CDATA[Magazine]]></category>
		<category><![CDATA[Postings]]></category>
		<category><![CDATA[advisory vote]]></category>
		<category><![CDATA[afl-cio]]></category>
		<category><![CDATA[Amazon.com]]></category>
		<category><![CDATA[AOL]]></category>
		<category><![CDATA[AT&T]]></category>
		<category><![CDATA[Barroway Topaz]]></category>
		<category><![CDATA[Biolase]]></category>
		<category><![CDATA[BMP Sunstone]]></category>
		<category><![CDATA[Brenda J. Mixson]]></category>
		<category><![CDATA[Carl Icahn]]></category>
		<category><![CDATA[Cibus Global]]></category>
		<category><![CDATA[Daniel P. Harrington]]></category>
		<category><![CDATA[Darren Check]]></category>
		<category><![CDATA[David M. Cordani]]></category>
		<category><![CDATA[Debt Resolve]]></category>
		<category><![CDATA[DuPont]]></category>
		<category><![CDATA[Ellen Kullman]]></category>
		<category><![CDATA[Federal Communications]]></category>
		<category><![CDATA[Fortune 100]]></category>
		<category><![CDATA[Fredric G. Reynolds]]></category>
		<category><![CDATA[Grant Fitzwilliam]]></category>
		<category><![CDATA[Grant Lyon]]></category>
		<category><![CDATA[Gregory D. Waller]]></category>
		<category><![CDATA[H. Frederick Christie]]></category>
		<category><![CDATA[HFF]]></category>
		<category><![CDATA[Ironwood]]></category>
		<category><![CDATA[James A. Wiatt]]></category>
		<category><![CDATA[James Brakke]]></category>
		<category><![CDATA[James Huger]]></category>
		<category><![CDATA[James R. Stengel]]></category>
		<category><![CDATA[John P. Gaylord]]></category>
		<category><![CDATA[Karen E. Dykstra]]></category>
		<category><![CDATA[Legg Mason]]></category>
		<category><![CDATA[Malkon S. Baboyian]]></category>
		<category><![CDATA[Mark D. Gibson]]></category>
		<category><![CDATA[Marsha Fanucci]]></category>
		<category><![CDATA[Michael K. Powell]]></category>
		<category><![CDATA[Michael Larson]]></category>
		<category><![CDATA[Michael M. Clair]]></category>
		<category><![CDATA[Money4Gold]]></category>
		<category><![CDATA[nelson peltz]]></category>
		<category><![CDATA[New York Life Insurance Co.]]></category>
		<category><![CDATA[Oce North America]]></category>
		<category><![CDATA[Parkway Properties]]></category>
		<category><![CDATA[Patricia E. Mitchell]]></category>
		<category><![CDATA[Peter B. Coor]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Qualsec]]></category>
		<category><![CDATA[Ralph de la Vega]]></category>
		<category><![CDATA[Ralph J. Folz]]></category>
		<category><![CDATA[Republic Services]]></category>
		<category><![CDATA[Revlon]]></category>
		<category><![CDATA[RHR International]]></category>
		<category><![CDATA[Richard Dalzell]]></category>
		<category><![CDATA[Richard F. Seelig]]></category>
		<category><![CDATA[Richard J. Santagati]]></category>
		<category><![CDATA[Richard R. Stewart]]></category>
		<category><![CDATA[Seneca Foods]]></category>
		<category><![CDATA[SouthWest Water]]></category>
		<category><![CDATA[Stephen Palm]]></category>
		<category><![CDATA[Susan P. McGalla]]></category>
		<category><![CDATA[TAS]]></category>
		<category><![CDATA[The Digital Living Network Alliance]]></category>
		<category><![CDATA[Thomas J. Saporito]]></category>
		<category><![CDATA[Tim Armstrong]]></category>
		<category><![CDATA[Time Warner]]></category>
		<category><![CDATA[Vitesse]]></category>
		<category><![CDATA[William R. Hambrecht]]></category>
		<category><![CDATA[WordStream]]></category>
		<category><![CDATA[Yahoo]]></category>

		<guid isPermaLink="false">http://www.directorship.com/postings-pfizer%e2%80%99s-board-formalizes-advisory-vote/</guid>
		<description><![CDATA[Pfizer is the latest company to approve giving shareholders an advisory vote on executive compensation. ]]></description>
			<content:encoded><![CDATA[<p>As compensation continues to be scrutinized by the public and the government, some of the country’s largest firms are taking steps to ease shareholders’ concerns long before proxy battles are launched. Pfizer is the latest company to approve giving shareholders an advisory vote on executive compensation. The first vote will take place at Pfizer’s annual meeting in 2010 and will occur on a biennial basis after that.</p>
<p>“It’s a great step for Pfizer; more and more companies are being proactive [about communicating with shareholders],” says Darren Check, partner at Barroway Topaz, a shareholder class-   action firm. Pfizer has held informal sit-downs with shareholders for the past few years. “It has to do with the attitude at the top of the company,” notes Check. “What’s key is having the right CEO who has an attitude that shareholders are the owners of these companies and they should have a platform to be heard.”</p>
<p>Pfizer isn’t alone.  Aflac, Occidental, Bristol-Meyers Squibb, and Microsoft have all taken similar steps to lend shareholders a voice regarding executive compensation. “I believe that soon, smaller companies will begin to make similar changes,” predicts Robert E. McGarrah Jr., counsel of the AFL-CIO Office of Investment.</p>
<p>The House Financial Services Committee recently approved the Private Fund Investment Advisers Registration Act of 2009, a bill that would require investment advisers of hedge funds, private-equity funds, and other private pools of capital to register with the Securities and Exchange Commission. The bill is part of larger financial regulatory reform legislation, which seeks to curb excessive executive pay practices.</p>
<p>McGarrah reflected on a recent meeting involving a Fortune 100 company that is taking a ‘wait and see’ approach. “A com-pany can take its chances that Congress isn’t going to mandate anything, or it can step up to the plate and recognize that this [shareholder advisory voting] makes sense and is a mainstream     issue,” says McGarrah. “We are strongly in favor of Pfizer’s decision—but we’d like to see them [and other companies] take it further and introduce an annual vote.”           </p>
]]></content:encoded>
			<wfw:commentRss>http://www.directorship.com/pfizer-advisory-vote/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer CEO describes new transparency</title>
		<link>http://www.directorship.com/pfizer-ceo/</link>
		<comments>http://www.directorship.com/pfizer-ceo/#comments</comments>
		<pubDate>Wed, 02 Dec 2009 21:07:13 +0000</pubDate>
		<dc:creator>News Editor</dc:creator>
				<category><![CDATA[Boardroom News]]></category>
		<category><![CDATA[Directors Daily Briefing]]></category>
		<category><![CDATA[Newsletters]]></category>
		<category><![CDATA[drug industry]]></category>
		<category><![CDATA[Jeffery B. Kindler]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.directorship.com/?p=13127</guid>
		<description><![CDATA[Pfizer CEO Jeffrey B. Kindler: "It's up to us to earn back the trust we've lost." ]]></description>
			<content:encoded><![CDATA[<p>Pfizer CEO Jeffrey B. Kindler describes multiple operational changes as a result of the largest prescription drug criminal-fraud case in U.S. history that resulted in $2.3 billion in civil and criminal penalties. According to the <a href="http://www.bostonherald.com/business/healthcare/view.bg?articleid=1215928&amp;position=0" target="_blank"><strong><em>Boston Herald,</em></strong></a> Kindler said: &#8220;It&#8217;s up to us to earn back the trust we&#8217;ve lost,&#8221; during a speech Dec. 1 to the Boston College Chief Executives Club.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.directorship.com/pfizer-ceo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pfizer to Pay Record $2.3B Settlement</title>
		<link>http://www.directorship.com/pfizer-to-pay-2-3b-settlement/</link>
		<comments>http://www.directorship.com/pfizer-to-pay-2-3b-settlement/#comments</comments>
		<pubDate>Thu, 03 Sep 2009 10:01:54 +0000</pubDate>
		<dc:creator>News Editor</dc:creator>
				<category><![CDATA[Directors Daily Briefing]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Newsletters]]></category>
		<category><![CDATA[ethics]]></category>
		<category><![CDATA[litigation]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceuticals]]></category>
		<category><![CDATA[settlement]]></category>

		<guid isPermaLink="false">http://www.directorship.com/?p=9349</guid>
		<description><![CDATA[Pfizer will pay a record fine to settle allegations that it improperly marketed its drugs.]]></description>
			<content:encoded><![CDATA[<p>Drug maker Pfizer will pay a record fine of $2.3 billion to settle allegations that it improperly pushed several of its products on patients and physicians alike, according to <a title="Go to full story." href="http://www.reuters.com/article/newsOne/idUSTRE5813XB20090902" target="_blank"><strong>Reuters</strong></a>. Prosecutors alleged that Pfizer promoted 13 of its drugs for improper uses and doses, including Bextra, a drug meant to treat symptoms associated with arthritis. Pfizer paid $1.3 billion for its false marketing of Bextra as a broader paint treatment drug, as well as a $1 billion civil payment. “We regret certain actions taken in the past, but are proud of the action we&#8217;ve taken to strengthen our internal controls, said Amy Schulman, Pfizer’s general counsel.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.directorship.com/pfizer-to-pay-2-3b-settlement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

